| Note |
Therapeutic novelty. Recit. Atomoxetine. 10 18 25 40 60mg. New structure. New activity. Intelligent molecule*. *Atomoxetine increases the synaptic levels of NA and DA exclusively in the prefrontal cortex. Towards organized learning. First non-stimulating molecule approved by the FDA for the treatment of ADHD in children, adolescents and adults. Continuous symptomatic and functional relief, during 24hrs with only one dose. Re-establishes the development and performance of the executive functions. Does not alter sleeping patterns. Cardiovascular security and excellent tolerability. Does not need an official prescription*. *Patient record required for psychostimulants. Visit our website: www.recit.com.ar |
